Story
Eli Lilly Can Continue Weight-Loss Drug Ads After Judge Denies Novo Nordisk Injunction
A U.S. federal judge has denied Novo Nordisk's request for a preliminary injunction against rival Eli Lilly, allowing Lilly to continue its direct-to-consumer advertising for its popular weight-loss drugs. The ruling marks a setback for Novo Nordisk in the high-stakes legal and commercial battle between the two pharmaceutical giants.
The Court's Decision
U.S. District Judge Zahid Quraishi in Trenton, New Jersey, on Monday rejected the motion from Novo Nordisk, which had sought to temporarily halt Eli Lilly's ad campaigns while the underlying lawsuit proceeds. A preliminary injunction is an extraordinary measure granted before a final decision in a case.
In his ruling, Judge Quraishi determined that Novo Nordisk's claim of suffering irreparable harm from the advertisements was "inadequate to warrant the extraordinary relief it seeks," according to the court filing.
The Core of the Dispute
Novo Nordisk filed the lawsuit against Eli Lilly in July, alleging that its competitor's ads for the obesity drug Zepbound and diabetes treatment Mounjaro were false and misleading. The Danish drugmaker claimed these ads violated federal laws on false advertising and unfair competition.
AdThe central allegation is that Eli Lilly's advertisements improperly compared higher doses of its products with lower doses of Novo Nordisk's competing drugs, Wegovy and Ozempic. Novo Nordisk argued this created a deceptive impression of superior efficacy. Eli Lilly has denied any wrongdoing in the case.
Market Implications
The decision is a tactical win for Eli Lilly, allowing it to maintain its current marketing momentum in the lucrative U.S. market. The United States is one of the few major economies that permits direct-to-consumer advertising for prescription medications, making it a critical battleground for market share.
This legal dispute underscores the intense competition for dominance in the global market for injectable obesity drugs, which analysts project could exceed $100 billion by the end of the decade. For investors, the outcome of these legal and marketing skirmishes is a key factor in evaluating the growth prospects of both companies.
Read next
More on Stocks
JetBlue Stock Rebounds After-Hours on Better-Than-Feared Q3 Results
Shares of JetBlue Airways recovered from a record intraday low, surging in extended trading after its third-quarter results eased investor concerns about the airline's financial health.
HyProMag USA Plans $656M Expansion to Quadruple US Rare Earth Magnet Output
Rare earth magnet recycler HyProMag USA has unveiled plans for three new U.S. facilities, an expansion estimated to cost up to $656 million that would quadruple its planned domestic production capacity.
Applied Materials to Boost Stake in BESI to 20% to Deepen AI Chip Partnership
The U.S. semiconductor equipment giant will increase its holding in the Dutch firm from 9% to approximately 20% to advance their collaboration on critical chip-packaging technologies for AI applications.
Universal Music Group Explored Take-Private Deal with Apollo, Blackstone, TPG, Bloomberg Reports
The world's largest music company reportedly held preliminary discussions with several major private equity firms earlier this year about a potential deal to take it private, according to Bloomberg News.